COALITION TO CURE CALPAIN 3

OVERCOMING WEAKNESS WITH STRENGTH

Coalition to Cure Calpain 3 (C3) is committed to treating and ultimately curing limb girdle muscular dystrophy type 2A (LGMD2A)/calpainopathy.

Our mission is to fund high potential research and clinical trials as we educate the global community about this rare disease.

C3 is a 501(c)(3) US-based tax-exempt charity.

What is calpain 3 deficiency (calpainopathy)?

- A problem with an enzyme necessary for muscles to function properly, caused by a genetic mutation
- A progressive disease that causes muscle weakness, ultimately resulting in loss of the ability to walk
- One of the most common types of limb-girdle muscular dystrophy (LGMD2A)

No treatment or cure is currently available, but there are several promising potential areas of research.

How can you learn more about what C3 does to help?

- Visit www.CureCalpain3.org to join our email list and to learn more about our initiatives
  - Funding essential research to understand the workings of the disease and identify treatments
  - Organizing scientific conferences to bring together researchers and clinicians to foster collaboration
  - Supporting efforts to develop an inexpensive and reliable diagnostic test

And how can you become engaged?

- Join the global patient registry at www.LGMD2A.org
- Connect with our Facebook group "C3 Community" to share information and support with other affected individuals and families at www.facebook.com/groups/LGMD2A

"Calpain 3 (LGMD2A) is among the most common of the muscular dystrophies, but research… and existence of clinical trials is woefully underrepresented.

From the limited amount we know about calpain 3 deficiency, it seems to be one of the most 'curable' of the muscular dystrophies."

Eric Hoffman, PhD
Director, Research Center for Genetic Medicine, Children's National Medical Center, Washington DC

"LGMD2A is caused by mutations in an enzyme called calpain 3. This mutation is vastly different from most of the other muscular dystrophies that involve mutations in structural proteins.

Thus, it is absolutely essential that C3 exists to specifically fund research and treatment of calpainopathies."

Melissa Spencer, PhD
Co-Director, Center for Duchenne Muscular Dystrophy,, UCLA

To donate or to learn more, please visit us at www.CureCalpain3.org.